TLR2 activation with Pam3CSK4 increases survival in local IFC–ACS–derived neutrophils (A), but neither in systemic IFC–ACS neutrophils (B), nor in RFC–ACS–derived neutrophils in general (A for local, B for systemic); data are expressed as a ratio of CD16lo vs. CD16hi neutrophils. Repeated measures ANOVA with Bonferroni’s multiple comparisons test; data are presented as a median with interquartile range (IQR); n = 8 per group; effect size η² after repeated measures ANOVA (small effect η² < 0.01, medium effect η² between 0.01 and 0.14, large effect η² > 0.14). Pam3CSK4, Toll-like receptor 2 ligand; IFC–ACS, acute coronary syndrome with intact fibrous cap; RFC–ACS, acute coronary syndrome with ruptured fibrous cap.